Cambridge Healthtech Instituteのトレーニングセミナーでは、学術的な理論や背景を幅広くカバーするとともに、実際の事例研究や遭遇した問題、適用されたソリューションを提供します。各トレーニングセミナーでは、正式な講義と双方向の討論・行動を組み合わせて、学習体験を最大化することができます。トレーニングセミナーは、経験豊富なインストラクターが担当し、現在の研究に応用可能な内容に焦点を当てると共に、この分野に不慣れな方にも重要なガイダンスを提供します。
トレーニングセミナーは対面形式でのみ開催されます。
2024年1月16日(火)午前9:00〜午後5:45|2024年1月17日(水)午前11:05〜午後2:00
TS6A: Introduction to Multispecific Antibodies
Topics to be Covered:
- A brief history of bispecific antibodies: 60 years of progress with critical advances and key pioneers
- Bispecific applications and powerful mechanisms-of-action
- Engineering bispecific antibodies:100 formats and counting
- Bispecific-specific considerations in preclinical development and regulatory landscape
- Developability, manufacturing, and analytical considerations
- Clinical experience, translation, and regulatory approval
- Current trends and future opportunities in regulating immune checkpoints, cell-based therapies, and personalized approaches
INSTRUCTOR BIOGRAPHIES:
G. Jonah Rainey, PhD, Senior Director, Protein Engineering, Eli Lilly and Company
TS7A: Introduction to Antibody Engineering
Antibody Background
- Structure
- Genes
- Generation of Diversity (recombination, somatic hypermutations)
Antibody Humanization
- Closest human gene approach
- Minimal modification approach
- Veneering
Display Technologies Overview
- Phage
- Yeast
- Combining phage and yeast display
- Ribosome
- Others
Generation of Naive Antibody Libraries
- Natural libraries (methods, quality control)
- Synthetic libraries (including strategies for generation diversity)
Affinity Maturation
- Error-prone PCR
- Chain shuffling
- CDR-targeted mutations
Next-Generation Sequencing in Antibody Engineering
- Platforms: advantages and disadvantages
- Error rates and why they are important
- Naive library diversity analysis
- Selection analysis
Antibody Characterization and Developability
- Expression
- Specificity
- Aggregation
- Solubility
INSTRUCTOR BIOGRAPHIES:
Andrew R.M. Bradbury, PhD, CSO, Specifica, Inc.
James D. Marks, MD, PhD, Professor and Vice Chairman, Department of Anesthesia and Perioperative Care, University of California, San Francisco (UCSF); Chief of Performance Excellence, Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG)
TS8A: Introduction to Machine Learning for Biologics Design
- Basics of machine learning and where it fits into drug discovery
- Machine learning: a historical view of its application in the field of drug discovery
- How machine learning revolutionized homology modeling
- Applying machine learning to structure-based biologics design
- Guiding the design of display libraries using machine learning
INSTRUCTOR BIOGRAPHIES:
Christopher R. Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
Francis Gaudreault, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
TS9A: Advanced Purification of Engineered Biologics and Research Protein Tools
Learning points:
- Surface chemistry of proteins and their behaviors in aqueous buffers
- Protein-monodispersing elements for “sticky” proteins and clearance of low abundance product degrading and destabilizing impurities
- Protein aggregates and aggregate clearance strategies
- Old semi-automated robots for 24/96-format HT-panel protein purification
- A novel hybrid HT-magnetic bead/resin-based purification robot for 6(x50ml), 24(x4ml), and 96(x1ml) formats
- Side products clearance from biologics using purification promoting mutations
- Protein purification tags and traceless engineering/purification tags for generating mutation-free bispecific molecules
- High-speed HT-low protein consumptive analytics for protein panels
Who should attend?
Although this course is directed towards protein purification experts in the fields of biologics and proteomics, biologics engineers and experienced scientists in general protein purification will find it very useful.
INSTRUCTOR BIOGRAPHIES:
John K. Kawooya, PhD, Private Consultant of Robotics-Plate-Based-Ultra-HT Biologics Purification
2024年1月18日(木)午前8:30〜午後4:45|2024年1月19日(金)午前9:00〜午後1:00
TS6B: Biomanufacturing 101: An Overview on Animal Cell Culture Technology from Cell Line Development to Scale-Up Strategies
Training Seminar Outline:
- Historical development and progress of animal cell culture technology
- Animal cells as factories for production of biopharmaceutical products
- Understanding the cell cycle at the molecular level and how it will impact cell productivity
- Expression systems and transfection assays
- Cell Line development, clone selection, cell line characterization and cell line banking.
- The importance of nutrients and media design for specific cells and clones
- Understanding scale-up issues in bioprocessing and how to scale-up your process with detailed description of hollow fiber, microcarrier and stirred-tank bioreactor systems
- Case studies
INSTRUCTOR BIOGRAPHIES:
Kamal A. Rashid, PhD, President, International Biotechnology Associates
TS7B: Introduction to CMC for Biotech, Cell & Gene Therapy Products
The chemistry manufacturing and controls (CMC) of biologics is a multidiscipline technical operation of bioprocess, analytics, dosage formulation, and cGMP manufacturing/testing for DS/DP release and stability to treat human diseases. This interactive training course will provide a comprehensive CMC overview of therapeutic biological products. It introduces a variety of therapeutic modalities including recombinant proteins, monoclonal antibodies (Mab), and cell and gene therapy (CGT) in the context of IMPD and IND regulatory filing. Attendees will learn scientific, technical, and operational aspects of overall biologics CMC activities as well as quality compliance and regulatory requirements. The instructor will present common pitfalls and share the best industry practices. Numerous real-world regulatory queries/comments from health authorities worldwide will be exemplified as case studies during the training course.
TOPICS TO BE COVERED:
1. Diverse modality of therapeutic biological products
2. Biologics CMC activities for regulatory filing (IMPD/IND)
3. Quality by design (QbD) concept, quality target product profile (QTPP), and critical quality attributes (CQA)
4. Cell line development, process development, and manufacture of biologics, CGT DS and DP
5. Current analytical technologies to characterize product variants/impurities, process impurities (e.g., HCP), and contaminants
6. Formulation development and compatibility with container closures and injection devices
7. Reference material characterization/qualification and justification of specifications for DS/DP release and ICH stability for product expiry
8. Process validation, analytical validation, and control strategy of cGMP manufacturing
9. Manufacturing process changes during product development lifecycle: CMC comparability exercise
WHO SHOULD ATTEND: The course is beneficial to individuals involved in biologics drug research/development, bioprocess development, analytical development, formulation development, quality control, quality assurance, regulatory affairs, project management, or related functional areas.
INSTRUCTOR BIOGRAPHIES:
Kevin Zen, PhD, Senior Director, IGM Biosciences
TS8B: Label-Free Biosensor Tools in Biotherapeutic Discovery: SPR, BLI & KinExA
Day 1: How, What & Why-Choosing the Best Tool for the Job
- Non-covalent reversible interactions
- Limitations of endpoint assays
- Introduction to binding kinetic parameters
- Clinical relevance
- Surface-based methods and introducing the concept of ligand and analyte
- Solution-phase methods and introducing the concept of constant binding partner (CBP) and titrant
- Advantages and limitations of each platform
- Factors affecting binding assays
- Minimizing artifacts
- Qualitative vs. quantitative assays
- Data analysis and interpretation
- Sample requirements
- Assay orientation
- Dynamic range
- Time to equilibrium
- Data analysis and interpretation
- Rationale for using KinExA
- Optimal experimental design for studying ultra-high affinities
- Optimal reagent requirements for on-cell measurements
- Rationale for performing blocking assays
- Designing blocking assays
- Case studies
- Pairwise antibody competition assays
- Bin definition
- Throughput
- Impact of antigen heterogeneity
- Asymmetric binnings
- Antibody displacement
Day 2: Good, Bad & Ugly
8. Case Study: Characterizing the FcRn/IgG interaction
- Analyzing a pH-sensitive interaction
- Use of complementary biosensor assay formats
- Avidity matters in extending serum half life
9. Group Exercise: SPR, BLI & KinExA
- Evaluating Good, Bad & Ugly in the published literature
10. Group Exercise: Complementary use of surface and solution methods in affinity determinations
- Literature review
INSTRUCTOR BIOGRAPHIES:
Yasmina Abdiche, PhD, Vice President, Exploratory Research, OmniAb Inc.
Vishal Kamat, PhD, Senior Director, Protein Sciences, Ampersand Biomedicines
Palaniswami (Swami) Rathanaswami, PhD, CEO, PRSwami AbDev Inc.
TS9B: Antibody Drug Discovery: From Target to Lead
Topics to be covered include:
Different Sources of Antibodies
- Animals: mouse, rat, rabbit, chicken, llama, etc.
- Libraries: immune, synthetic, native, fully human, etc.
- B cells: memory B cells, plasma B cells, human, and animals
Antibody-Based Drug Modalities
- IgGs, IgA, IgM, Bites, nanobody, antibody fragments, etc.
- Naked antibody
- ADC
- Bispecific/multispecific
- CAR T
Antibody Engineering
- Affinity maturation
- Humanization
- Fc-engineering: half-life, immune effector function, etc.
Target Selection and Validation
Antibodies Targeting Complex Membrane Proteins
- GPCRs
- Ion channels
- Transporters and membrane-bound enzymes
Delivery of Antibodies Crossing the Brain-Blood Barrier (BBB)
Case Studies
INSTRUCTOR BIOGRAPHIES:
Zhiqiang An, PhD, Professor, Robert A. Welch Distinguished University Chair in Chemistry; Director, Texas Therapeutics Institute; Director, CPRIT Core for Antibody Drug Discovery; Vice President, Drug Discovery, University of Texas Health Science Center at Houston
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。
講演者・スポンサー更新
講演者・スポンサー更新
Premier Sponsor
プログラム
抗体探索・エンジニアリング二重特異性抗体の探索
生物学的製剤・ワクチンの特性評価
ベクターの設計と送達
生物学的製剤の発現と生産
トレーニングセミナー